Selected research
Market Structure
Global Neuropeptide Y Receptor Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Neuropeptide Y Receptor market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.
The US & Canada market for Neuropeptide Y Receptor is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Neuropeptide Y Receptor is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Neuropeptide Y Receptor is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Neuropeptide Y Receptor is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Neuropeptide Y Receptor include Gila Therapeutics, Novo Nordisk, XL-protein, Lilly Eli, Novartis, Pfizer, Merck & Co, Mannkind and Gilead Sciences, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Neuropeptide Y Receptor market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Neuropeptide Y Receptor and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Neuropeptide Y Receptor sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Neuropeptide Y Receptor market size, projected growth trends, production technologies, key applications, and end-use industries.
Neuropeptide Y Receptor Segment by Company
Gila Therapeutics
Novo Nordisk
XL-protein
Lilly Eli
Novartis
Pfizer
Merck & Co
Mannkind
Gilead Sciences
Genentech
Neuropeptide Y Receptor Segment by Type
Food Grade
Pharmaceutical Grade
Neuropeptide Y Receptor Segment by Application
Medicine
Food Additives
Others
Neuropeptide Y Receptor Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Neuropeptide Y Receptor market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Neuropeptide Y Receptor and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Neuropeptide Y Receptor.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Neuropeptide Y Receptor market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Neuropeptide Y Receptor manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Neuropeptide Y Receptor in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Neuropeptide Y Receptor in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Food Grade
- Pharmaceutical Grade
Applications
- Medicine
- Food Additives
- Others
Companies covered
- Gila Therapeutics
- Novo Nordisk
- XL-protein
- Lilly Eli
- Novartis
- Pfizer
- Merck & Co
- Mannkind
- Gilead Sciences
- Genentech
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Neuropeptide Y Receptor Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Neuropeptide Y Receptor Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Neuropeptide Y Receptor Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Neuropeptide Y Receptor Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Neuropeptide Y Receptor Market Dynamics
- 2.1 Neuropeptide Y Receptor Industry Trends
- 2.2 Neuropeptide Y Receptor Industry Drivers
- 2.3 Neuropeptide Y Receptor Industry Opportunities and Challenges
- 2.4 Neuropeptide Y Receptor Industry Restraints
3 Neuropeptide Y Receptor Market by Manufacturers
- 3.1 Global Neuropeptide Y Receptor Revenue by Manufacturers (2021-2026)
- 3.2 Global Neuropeptide Y Receptor Sales by Manufacturers (2021-2026)
- 3.3 Global Neuropeptide Y Receptor Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Neuropeptide Y Receptor Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Neuropeptide Y Receptor Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Neuropeptide Y Receptor Manufacturers, Product Type & Application
- 3.7 Global Neuropeptide Y Receptor Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Neuropeptide Y Receptor Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Neuropeptide Y Receptor Players Market Share by Revenue in 2025
- 3.8.3 2025 Neuropeptide Y Receptor Tier 1, Tier 2, and Tier 3
4 Neuropeptide Y Receptor Market by Type
- 4.1 Neuropeptide Y Receptor Type Introduction
- 4.1.1 Food Grade
- 4.1.2 Pharmaceutical Grade
- 4.2 Global Neuropeptide Y Receptor Sales by Type
- 4.2.1 Global Neuropeptide Y Receptor Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Neuropeptide Y Receptor Sales by Type (2021-2032)
- 4.2.3 Global Neuropeptide Y Receptor Sales Market Share by Type (2021-2032)
- 4.3 Global Neuropeptide Y Receptor Revenue by Type
- 4.3.1 Global Neuropeptide Y Receptor Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Neuropeptide Y Receptor Revenue by Type (2021-2032)
- 4.3.3 Global Neuropeptide Y Receptor Revenue Market Share by Type (2021-2032)
5 Neuropeptide Y Receptor Market by Application
- 5.1 Neuropeptide Y Receptor Application Introduction
- 5.1.1 Medicine
- 5.1.2 Food Additives
- 5.1.3 Others
- 5.2 Global Neuropeptide Y Receptor Sales by Application
- 5.2.1 Global Neuropeptide Y Receptor Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Neuropeptide Y Receptor Sales by Application (2021-2032)
- 5.2.3 Global Neuropeptide Y Receptor Sales Market Share by Application (2021-2032)
- 5.3 Global Neuropeptide Y Receptor Revenue by Application
- 5.3.1 Global Neuropeptide Y Receptor Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Neuropeptide Y Receptor Revenue by Application (2021-2032)
- 5.3.3 Global Neuropeptide Y Receptor Revenue Market Share by Application (2021-2032)
6 Global Neuropeptide Y Receptor Sales by Region
- 6.1 Global Neuropeptide Y Receptor Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Neuropeptide Y Receptor Sales by Region (2021-2032)
- 6.2.1 Global Neuropeptide Y Receptor Sales by Region (2021-2026)
- 6.2.2 Global Neuropeptide Y Receptor Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Neuropeptide Y Receptor Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Neuropeptide Y Receptor Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Neuropeptide Y Receptor Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Neuropeptide Y Receptor Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Neuropeptide Y Receptor Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Neuropeptide Y Receptor Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Neuropeptide Y Receptor Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Neuropeptide Y Receptor Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Neuropeptide Y Receptor Revenue by Region
- 7.1 Global Neuropeptide Y Receptor Revenue by Region
- 7.1.1 Global Neuropeptide Y Receptor Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Neuropeptide Y Receptor Revenue by Region (2021-2026)
- 7.1.3 Global Neuropeptide Y Receptor Revenue by Region (2027-2032)
- 7.1.4 Global Neuropeptide Y Receptor Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Neuropeptide Y Receptor Revenue (2021-2032)
- 7.2.2 North America Neuropeptide Y Receptor Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Neuropeptide Y Receptor Revenue (2021-2032)
- 7.3.2 Europe Neuropeptide Y Receptor Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Neuropeptide Y Receptor Revenue (2021-2032)
- 7.4.2 Asia-Pacific Neuropeptide Y Receptor Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Neuropeptide Y Receptor Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Neuropeptide Y Receptor Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 Gila Therapeutics
- 8.1.1 Gila Therapeutics Company Information
- 8.1.2 Gila Therapeutics Business Overview
- 8.1.3 Gila Therapeutics Neuropeptide Y Receptor Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 Gila Therapeutics Neuropeptide Y Receptor Product Portfolio
- 8.1.5 Gila Therapeutics Recent Developments
- 8.2 Novo Nordisk
- 8.2.1 Novo Nordisk Company Information
- 8.2.2 Novo Nordisk Business Overview
- 8.2.3 Novo Nordisk Neuropeptide Y Receptor Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 Novo Nordisk Neuropeptide Y Receptor Product Portfolio
- 8.2.5 Novo Nordisk Recent Developments
- 8.3 XL-protein
- 8.3.1 XL-protein Company Information
- 8.3.2 XL-protein Business Overview
- 8.3.3 XL-protein Neuropeptide Y Receptor Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 XL-protein Neuropeptide Y Receptor Product Portfolio
- 8.3.5 XL-protein Recent Developments
- 8.4 Lilly Eli
- 8.4.1 Lilly Eli Company Information
- 8.4.2 Lilly Eli Business Overview
- 8.4.3 Lilly Eli Neuropeptide Y Receptor Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.4.4 Lilly Eli Neuropeptide Y Receptor Product Portfolio
- 8.4.5 Lilly Eli Recent Developments
- 8.5 Novartis
- 8.5.1 Novartis Company Information
- 8.5.2 Novartis Business Overview
- 8.5.3 Novartis Neuropeptide Y Receptor Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.5.4 Novartis Neuropeptide Y Receptor Product Portfolio
- 8.5.5 Novartis Recent Developments
- 8.6 Pfizer
- 8.6.1 Pfizer Company Information
- 8.6.2 Pfizer Business Overview
- 8.6.3 Pfizer Neuropeptide Y Receptor Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.6.4 Pfizer Neuropeptide Y Receptor Product Portfolio
- 8.6.5 Pfizer Recent Developments
- 8.7 Merck & Co
- 8.7.1 Merck & Co Company Information
- 8.7.2 Merck & Co Business Overview
- 8.7.3 Merck & Co Neuropeptide Y Receptor Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.7.4 Merck & Co Neuropeptide Y Receptor Product Portfolio
- 8.7.5 Merck & Co Recent Developments
- 8.8 Mannkind
- 8.8.1 Mannkind Company Information
- 8.8.2 Mannkind Business Overview
- 8.8.3 Mannkind Neuropeptide Y Receptor Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.8.4 Mannkind Neuropeptide Y Receptor Product Portfolio
- 8.8.5 Mannkind Recent Developments
- 8.9 Gilead Sciences
- 8.9.1 Gilead Sciences Company Information
- 8.9.2 Gilead Sciences Business Overview
- 8.9.3 Gilead Sciences Neuropeptide Y Receptor Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.9.4 Gilead Sciences Neuropeptide Y Receptor Product Portfolio
- 8.9.5 Gilead Sciences Recent Developments
- 8.10 Genentech
- 8.10.1 Genentech Company Information
- 8.10.2 Genentech Business Overview
- 8.10.3 Genentech Neuropeptide Y Receptor Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.10.4 Genentech Neuropeptide Y Receptor Product Portfolio
- 8.10.5 Genentech Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Neuropeptide Y Receptor Value Chain Analysis
- 9.1.1 Neuropeptide Y Receptor Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Neuropeptide Y Receptor Production Mode & Process
- 9.2 Neuropeptide Y Receptor Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Neuropeptide Y Receptor Distributors
- 9.2.3 Neuropeptide Y Receptor Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst